Literature DB >> 16959610

Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.

Yin Wang1, Yan Liu, Cindy Wu, Huiming Zhang, Xincheng Zheng, Zhi Zheng, Terrence L Geiger, Gerard J Nuovo, Yang Liu, Pan Zheng.   

Abstract

The genetic mechanisms responsible for increased incidence of lymphoma in immunocompromised individuals have not been fully elucidated. We show that, in a line of TCR transgenic TG-B mice, an insertional mutation in one allele of the Epm2a locus and epigenetic silencing of another led to a high rate of lymphoma with early onset. Overexpressing Epm2a suppressed the growth of established tumor cells and the development of lymphoma in the TG-B mice, while specific silencing of the locus increased tumorigenesis in the immune-deficient host. Downregulation of Epm2a expression is widespread among mouse and human lymphoma cell lines. Epm2a-encoded laforin is a phosphatase for GSK-3beta and an important repressor in the Wnt signaling pathway. Inactivation of Epm2a resulted in increased Wnt signaling and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959610     DOI: 10.1016/j.ccr.2006.08.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  29 in total

1.  NF1 inactivation in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Peter Ouillette; Yin Wang; Yan Liu; Whitney Wright; Diane Roulston; Anjali Purkayastha; Amanda Dressel; Judith Karp; Paula Bockenstedt; Ammar Al-Zoubi; Moshe Talpaz; Lisa Kujawski; Yang Liu; Kerby Shedden; Sajid Shakhan; Cheng Li; Harry Erba; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

Review 2.  Lafora disease, seizures and sugars.

Authors:  D M Andrade; J Turnbull; B A Minassian
Journal:  Acta Myol       Date:  2007-07

3.  Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.

Authors:  Carlos Romá-Mateo; Maria Del Carmen Solaz-Fuster; José Vicente Gimeno-Alcañiz; Vikas V Dukhande; Jordi Donderis; Carolyn A Worby; Alberto Marina; Olga Criado; Antonius Koller; Santiago Rodriguez De Cordoba; Matthew S Gentry; Pascual Sanz
Journal:  Biochem J       Date:  2011-10-15       Impact factor: 3.857

Review 4.  Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii.

Authors:  Matthew S Gentry; Carlos Romá-Mateo; Pascual Sanz
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

5.  Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.

Authors:  Yin Wang; Keli Ma; Peixiang Wang; Otto Baba; Helen Zhang; Jack M Parent; Pan Zheng; Yang Liu; Berge A Minassian; Yan Liu
Journal:  Mol Neurobiol       Date:  2013-04-02       Impact factor: 5.590

Review 6.  Glycogen and its metabolism: some new developments and old themes.

Authors:  Peter J Roach; Anna A Depaoli-Roach; Thomas D Hurley; Vincent S Tagliabracci
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

Review 7.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

8.  B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer.

Authors:  Penghui Zhou; Xincheng Zheng; Huiming Zhang; Yang Liu; Pan Zheng
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.

Authors:  Runhua Liu; Lizhong Wang; Chong Chen; Yan Liu; Penghui Zhou; Yin Wang; Xirui Wang; Julie Turnbull; Berge A Minassian; Yang Liu; Pan Zheng
Journal:  Mol Cell Biol       Date:  2008-09-29       Impact factor: 4.272

10.  Laforin, the most common protein mutated in Lafora disease, regulates autophagy.

Authors:  Carmen Aguado; Sovan Sarkar; Viktor I Korolchuk; Olga Criado; Santiago Vernia; Patricia Boya; Pascual Sanz; Santiago Rodríguez de Córdoba; Erwin Knecht; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-05-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.